Biomarker Potential of Preoperative Tumor Size in Determination of the Lymphovascular Invasion in Squamous Cell Lung Cancer and Lung Adenocarcinoma.
Lymphovascular invasion
nonsmall cell lung cancer
preoperative tumor size
Journal
International journal of applied & basic medical research
ISSN: 2229-516X
Titre abrégé: Int J Appl Basic Med Res
Pays: India
ID NLM: 101579831
Informations de publication
Date de publication:
Historique:
received:
04
08
2020
revised:
21
01
2021
accepted:
24
02
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
ppublish
Résumé
The invasion of blood and lymph vessels with tumor tissue represents a negative prognostic factor of the disease course in patients with non-small cell lung cancer. The aim of the study was to determine the marker value of a preoperatively determined size of pulmonary squamous cell carcinoma and adenocarcinoma and its impact on lymphovascular invasion (LVI) in resected lung tissue. The conducted observational cross-sectional study included 322 patients with a complete resection of confirmed squamous cell lung carcinoma and lung adenocarcinoma. Preoperative size and type of tumor were determined by a preoperative chest computed tomography scan and cytological/histological analysis of obtained samples, while LVI status was determined by pathohistological analysis of resected tumor lung tissue. Receiver operating characteristic (ROC) curve analysis was performed to assess whether tumor size could serve as a reliable marker for LVI. A statistically significant difference in the frequency of tumor size ( The preoperative size of lung adenocarcinoma could be an acceptable marker of LVI presence in resected lung tissue, while in the squamous cell lung cancer, a potential biomarker role of the preoperative size of the tumor was inadequate.
Identifiants
pubmed: 33912429
doi: 10.4103/ijabmr.IJABMR_500_20
pii: IJABMR-11-95
pmc: PMC8061604
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95-99Informations de copyright
Copyright: © 2021 International Journal of Applied and Basic Medical Research.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Ann Surg Oncol. 2011 Oct;18(10):2968-72
pubmed: 21512862
J Thorac Oncol. 2012 Jul;7(7):1141-7
pubmed: 22617241
J Thorac Cardiovasc Surg. 2018 Aug;156(2):785-793
pubmed: 29754785
Med Glas (Zenica). 2020 Feb 1;17(1):66-72
pubmed: 31736289
Lung Cancer. 2018 Jun;120:130-136
pubmed: 29748007
Eur J Cardiothorac Surg. 2012 Mar;41(3):603-6
pubmed: 22345182
Medicine (Baltimore). 2016 Jan;95(2):e2513
pubmed: 26765471
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Apr;10(4):682-90
pubmed: 25590605
J Thorac Oncol. 2014 Jun;9(6):818-24
pubmed: 24787961
Lung Cancer. 2014 Apr;84(1):13-22
pubmed: 24524818
Oncology. 2018;95(3):156-162
pubmed: 29847825
Ann Thorac Surg. 2014 Mar;97(3):965-71
pubmed: 24424014
Lung Cancer. 2018 Nov;125:245-252
pubmed: 30429028
J Thorac Oncol. 2015 Dec;10(12):1785-94
pubmed: 26473646
Radiology. 2019 Mar;290(3):807-813
pubmed: 30644810
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008